CY1105637T1 - Σπειροϋποκαθιστουμενες πυρρολοπυριμιδινες - Google Patents
Σπειροϋποκαθιστουμενες πυρρολοπυριμιδινεςInfo
- Publication number
- CY1105637T1 CY1105637T1 CY20061101408T CY061101408T CY1105637T1 CY 1105637 T1 CY1105637 T1 CY 1105637T1 CY 20061101408 T CY20061101408 T CY 20061101408T CY 061101408 T CY061101408 T CY 061101408T CY 1105637 T1 CY1105637 T1 CY 1105637T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cathepsin
- formula
- spiro substituted
- substituted pyrrolopyrimidines
- compounds
- Prior art date
Links
- 150000004944 pyrrolopyrimidines Chemical class 0.000 title 1
- 108090000625 Cathepsin K Proteins 0.000 abstract 2
- 102000004171 Cathepsin K Human genes 0.000 abstract 2
- 108090000613 Cathepsin S Proteins 0.000 abstract 2
- 102100035654 Cathepsin S Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Η εφεύρεση παρέχει ενώσεις του τύπου (Ι) ή ένα φαρμακευτικά αποδεκτό άλας ή εστέρα αυτού του τύπου (I) όπου τα σύμβολα έχουν την έννοια που ορίζεται στην περιγραφή. Οι εν λόγω ενώσεις είναι αναστολείς της καθεψίνης Κ ή / και της καθεψίνης S και είναι χρήσιμες για τη θεραπεία ασθενειών και ιατρικών καταστάσεων στις οποίες εμπλέκεται η καθεψίνη Κ ή / και η καθεψίνη S, π.χ. διάφορες διαταραχές όπως είναι ο νευροπαθητικός πόνος, η φλόγωση, η ρευματοειδής αρθρίτιδα, η οστεοαρθρίτιδα, η οστεοπόρωση, η πολλαπλή σκλήρωση και οι όγκοι.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0304640.6A GB0304640D0 (en) | 2003-02-28 | 2003-02-28 | Organic compounds |
PCT/EP2004/001982 WO2004076455A1 (en) | 2003-02-28 | 2004-02-27 | Spiro-substituted pyrrolopyrimidines |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1105637T1 true CY1105637T1 (el) | 2010-12-22 |
Family
ID=9953876
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20061101408T CY1105637T1 (el) | 2003-02-28 | 2006-09-28 | Σπειροϋποκαθιστουμενες πυρρολοπυριμιδινες |
Country Status (18)
Country | Link |
---|---|
US (2) | US7531546B2 (el) |
EP (1) | EP1601677B1 (el) |
JP (1) | JP2006519207A (el) |
CN (1) | CN100341876C (el) |
AT (1) | ATE331718T1 (el) |
AU (1) | AU2004215648B2 (el) |
BR (1) | BRPI0407919A (el) |
CA (1) | CA2517035A1 (el) |
CY (1) | CY1105637T1 (el) |
DE (1) | DE602004001397T2 (el) |
DK (1) | DK1601677T3 (el) |
ES (1) | ES2268633T3 (el) |
GB (1) | GB0304640D0 (el) |
HK (1) | HK1089156A1 (el) |
MX (1) | MXPA05009157A (el) |
PL (1) | PL378469A1 (el) |
PT (1) | PT1601677E (el) |
WO (1) | WO2004076455A1 (el) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
US8193208B2 (en) | 2005-09-09 | 2012-06-05 | Purdue Pharma L.P. | Fused and spirocycle compounds and the use thereof |
TW200804382A (en) * | 2005-12-05 | 2008-01-16 | Incyte Corp | Lactam compounds and methods of using the same |
US20080269241A1 (en) * | 2007-02-15 | 2008-10-30 | Darin Allen | Bicyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
US20090118274A1 (en) * | 2007-02-15 | 2009-05-07 | Darin Allen | Monocyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
US20080200454A1 (en) * | 2007-02-15 | 2008-08-21 | Ameriks Michael K | Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
US20090099157A1 (en) * | 2007-02-15 | 2009-04-16 | Ameriks Michael K | Tetrahydro-pyrazolo-pyridine thioether modulators of cathepsin s |
US20080207683A1 (en) * | 2007-02-15 | 2008-08-28 | Darin Allen | Biaryl-substituted tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
CA2685942A1 (en) * | 2007-05-16 | 2008-11-27 | Merck & Co., Inc. | Spiroindalones |
CN104974024B (zh) | 2008-03-21 | 2017-11-14 | 综合医院公司 | 检测和治疗阿尔茨海默病和相关疾病的化合物和组合物 |
MX2011013816A (es) | 2009-06-29 | 2012-04-11 | Incyte Corp | Pirimidinonas como inhibidores de pi3k. |
WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
US9193721B2 (en) | 2010-04-14 | 2015-11-24 | Incyte Holdings Corporation | Fused derivatives as PI3Kδ inhibitors |
US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
CA2822070C (en) | 2010-12-20 | 2019-09-17 | Incyte Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
ES2722524T3 (es) | 2011-09-02 | 2019-08-13 | Incyte Holdings Corp | Heterociclaminas como inhibidores de pi3k |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
JP6172143B2 (ja) * | 2012-04-17 | 2017-08-02 | アステラス製薬株式会社 | 含窒素二環式芳香族へテロ環化合物 |
JP6375300B2 (ja) * | 2012-10-16 | 2018-08-15 | ヤンセン・サイエンシズ・アイルランド・ユーシー | 抗rsvウイルス化合物 |
WO2014145576A2 (en) | 2013-03-15 | 2014-09-18 | Northwestern University | Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer |
TWI671299B (zh) | 2014-04-14 | 2019-09-11 | 愛爾蘭商健生科學愛爾蘭無限公司 | 作為rsv抗病毒化合物之螺脲化合物 |
US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
SG11201706917WA (en) | 2015-02-27 | 2017-09-28 | Incyte Corp | Salts of pi3k inhibitor and processes for their preparation |
WO2016179157A1 (en) | 2015-05-05 | 2016-11-10 | Carafe Drug Innovation, Llc | Substituted 5-hydroxyoxindoles and their use as analgesics and fever reducers |
US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
WO2016183060A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
CN107935908A (zh) * | 2016-10-12 | 2018-04-20 | 上海科胜药物研发有限公司 | 一种尼达尼布(nintedanib)的制备方法及其中间体 |
KR102709682B1 (ko) | 2018-03-28 | 2024-09-25 | 한림제약(주) | 2-시아노피리미딘-4-일 카르바메이트 혹은 유레아 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
US20240174695A1 (en) * | 2022-10-26 | 2024-05-30 | Protego Biopharma, Inc. | Spirocycle Containing Bicyclic Heteroaryl Compounds |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030225036A1 (en) | 2000-03-20 | 2003-12-04 | Aleksandr Kolesnikov | Non-amidine containing protease inhibitors |
GB0121033D0 (en) * | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
PE20050068A1 (es) * | 2003-02-06 | 2005-03-11 | Novartis Ag | 2-cianopirrolopirimidinas como inhibidores de la catepsina s |
-
2003
- 2003-02-28 GB GBGB0304640.6A patent/GB0304640D0/en not_active Ceased
-
2004
- 2004-02-27 AT AT04715273T patent/ATE331718T1/de not_active IP Right Cessation
- 2004-02-27 WO PCT/EP2004/001982 patent/WO2004076455A1/en active IP Right Grant
- 2004-02-27 EP EP04715273A patent/EP1601677B1/en not_active Expired - Lifetime
- 2004-02-27 US US10/547,184 patent/US7531546B2/en not_active Expired - Fee Related
- 2004-02-27 AU AU2004215648A patent/AU2004215648B2/en not_active Ceased
- 2004-02-27 JP JP2006501973A patent/JP2006519207A/ja active Pending
- 2004-02-27 ES ES04715273T patent/ES2268633T3/es not_active Expired - Lifetime
- 2004-02-27 BR BRPI0407919-1A patent/BRPI0407919A/pt not_active IP Right Cessation
- 2004-02-27 MX MXPA05009157A patent/MXPA05009157A/es active IP Right Grant
- 2004-02-27 CN CNB2004800054716A patent/CN100341876C/zh not_active Expired - Fee Related
- 2004-02-27 PT PT04715273T patent/PT1601677E/pt unknown
- 2004-02-27 DK DK04715273T patent/DK1601677T3/da active
- 2004-02-27 DE DE602004001397T patent/DE602004001397T2/de not_active Expired - Fee Related
- 2004-02-27 PL PL378469A patent/PL378469A1/pl not_active Application Discontinuation
- 2004-02-27 CA CA002517035A patent/CA2517035A1/en not_active Abandoned
-
2006
- 2006-06-01 HK HK06106349A patent/HK1089156A1/xx not_active IP Right Cessation
- 2006-09-28 CY CY20061101408T patent/CY1105637T1/el unknown
-
2009
- 2009-03-30 US US12/413,996 patent/US20090186889A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1601677A1 (en) | 2005-12-07 |
ES2268633T3 (es) | 2007-03-16 |
CN100341876C (zh) | 2007-10-10 |
DK1601677T3 (da) | 2006-10-30 |
CN1753895A (zh) | 2006-03-29 |
JP2006519207A (ja) | 2006-08-24 |
GB0304640D0 (en) | 2003-04-02 |
CA2517035A1 (en) | 2004-09-10 |
HK1089156A1 (en) | 2006-11-24 |
AU2004215648B2 (en) | 2007-10-11 |
PT1601677E (pt) | 2006-11-30 |
US7531546B2 (en) | 2009-05-12 |
DE602004001397D1 (de) | 2006-08-10 |
MXPA05009157A (es) | 2005-10-20 |
DE602004001397T2 (de) | 2007-04-26 |
US20060258690A1 (en) | 2006-11-16 |
PL378469A1 (pl) | 2006-04-03 |
ATE331718T1 (de) | 2006-07-15 |
BRPI0407919A (pt) | 2006-03-01 |
WO2004076455A1 (en) | 2004-09-10 |
EP1601677B1 (en) | 2006-06-28 |
US20090186889A1 (en) | 2009-07-23 |
AU2004215648A1 (en) | 2004-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1105637T1 (el) | Σπειροϋποκαθιστουμενες πυρρολοπυριμιδινες | |
CY1105573T1 (el) | Πυρρολο πυριμιδινες ως ανασταλτικοι παραγοντες των πρωτεασων κυστεϊνης | |
GB0220187D0 (en) | Organic compounds | |
CY1109908T1 (el) | 3,4-δι υποκατεστημενες κυκλοβουτενο-1,2-διονες σαν συνδετηρες υποδοχεα cxc-χημειοκινης | |
CY1109045T1 (el) | Ρετινοειδη για τη θεραπεια του εμφυσηματος | |
CY1105301T1 (el) | Αρυλοσυμπυκνωμενες αζαπολυκυκλικες ενωσεις | |
CY1107084T1 (el) | Παραγωγα πυρρολοπυριδαζινης | |
CY1108874T1 (el) | ΧΡΗΣΗ ΤΩΝ ΑΝΑΣΤΟΛΕΩΝ Ι κΒ- ΚΙΝΑΣΗΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΠΟΝΟΥ | |
DK1689233T3 (da) | Bicykliske inhibitorer af MEK | |
PL367821A1 (en) | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases | |
CY1108183T1 (el) | Θειαζολυλο-διυδρο-ινδαζολια | |
EA201400111A1 (ru) | Ингибиторы mek и способы их применения | |
CY1108894T1 (el) | Νεα παραγωγα βενζιμιδαζολης | |
CY1114521T1 (el) | Ενωσεις βενζαμιδιου χρησιμες ως αναστολεις αποακετυλασων ιστονων | |
CY1108625T1 (el) | Φαρμακευτικες συνθεσεις για τη χορηγηση απο το στομα ηπαρινης ή παραγωγων της | |
HN2004000150A (es) | Pirazoles como inhibidores de factor de necrosis tumoral | |
CY1112696T1 (el) | Παραγωγα 5-υδροξυμεθυλ-οξαζολιδιν-2-ονης | |
MXPA05007607A (es) | Inhibidores amida y ester de la metaloproteinasa de matriz. | |
NO20054361D0 (no) | Benzensylfonamidderivater, fremgangsmate for fremstilling og anvendelse derav for behandlig av smerte | |
EA200801894A1 (ru) | НОВЫЕ ЭНАНТИОМЕРНОЧИСТЫЕ β-АГОНИСТЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ СРЕДСТВ | |
ITMI20031130A1 (it) | Apparecchio per la distruzione di strumenti chirurgici. | |
DE60209709D1 (de) | Verfahren zur herstellung von chinazolinen | |
ITTO20010162A0 (it) | Perfezionamenti alle apparecchiature per il trattamento di tumori. |